Core Viewpoint - The court ruling against Koyuan Pharmaceutical's subsidiary, Shandong Linuo Pharmaceutical Co., Ltd., regarding a contract dispute with Jiangsu Saibang Pharmaceutical Co., Ltd. will directly impact the company's 2025 financial performance, leading to a significant reduction in net profit [1] Group 1: Financial Impact - The court ruling requires the company to recognize approximately 16.107 million yuan in non-operating expenses, which will reduce the net profit attributable to shareholders to an estimated range of 12.0897 million to 18.1345 million yuan, representing a decline of 70% to 80% compared to the previous year [1] - The adjustment only affects non-recurring profit and loss items, with the company's net profit excluding these items remaining unchanged at a range of 20.1171 million to 29.0581 million yuan, consistent with prior forecasts [1] Group 2: Legal Context - The contract dispute with Jiangsu Saibang Pharmaceutical has been ongoing, with some of Linuo Pharmaceutical's bank accounts previously frozen, affecting 57 million yuan, which is 4.19% of the company's latest audited net assets attributable to shareholders [2] - The first-instance ruling reduces uncertainty regarding the case, but the judgment is not yet effective as it is still within the appeal period [2] Group 3: Operational Performance - Despite the ongoing litigation, the company has been steadily advancing its business operations, with multiple new products set to launch in 2025, indicating a rich product pipeline [2] - Linuo Pharmaceutical's profitability has shown significant growth in the first half of 2025 compared to the same period last year, reflecting strong operational performance [2] - The company is also making strides in digital transformation, with its intelligent factory project in Jinan included in the provincial major industrial transformation reserve projects [2]
官司落槌确定性回归，科源制药各项业务稳步推进